This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamasaki, T. Articles by Hanaoka, M. Search for Related Content PubMed PubMed Citation Articles by Yamasaki, T. Articles by Hanaoka, M.

Specific Adoptive Immunotherapy with Tumor-specific Cytotoxic T-Lymphocyte Clone for Murine Malignant Gliomas¹

Department of Neurosurgery, Medical School [T. Y., H. H., J. Y.], and Departments of Molecular and Virology [Y. W.] and Pathology [Y. N., M. H.], Institute for Virus Research, Kyoto University, Kyoto, Japan

The efficacy of glioma-specific cytotoxic T-lymphocyte for a syngeneic murine malignant glioma (a 20-methylcholanthrene-induced ependymoblastoma, 203-glioma) was investigated. The cytotoxic clone (G-CTLL 1), established and expanded exponentially by T-cell growth factor, has retained target specificity for more than 6 months. In adoptive therapy and Winn assay, the in vivo antitumor activity of G-CTLL 1 was demonstrated against mice inoculated intracranially with 203-glioma cells. The therapeutic effects in adoptive immunotherapy were largely dependent on dose and time of i.v. administration, although the therapy was rather ineffective in condition of increased intracranial pressure due to the tumor growth. The mechanisms responsible for the in vivo protection were probably related to the killing activity of G-CTLL 1 or the tumor-specific production of immune interferon by G-CTLL 1.

¹ This work was supported by grants from Department of Neurosurgery, Kyoto University Medical School, Kyoto, Japan.

² To whom requests for reprints should be addressed, at Department of Neurosurgery, Kyoto University Medical School, 54-Kawaharacho, Schogoin, Sakyo-ku, Kyoto, 606 Japan.

Received 9/19/83. Accepted 1/25/84.

This article has been cited by other articles:

				K. S. Kahlon, C. Brown, L. J. N. Cooper, A. Raubitschek, S. J. Forman, and M. C. Jensen Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells Cancer Res., December 15, 2004; 64(24): 9160 - 9166. [Abstract] [Full Text] [PDF]

				C. H. Poehlein, H.-M. Hu, J. Yamada, I. Assmann, W. G. Alvord, W. J. Urba, and B. A. Fox TNF Plays an Essential Role in Tumor Regression after Adoptive Transfer of Perforin/IFN-{gamma} Double Knockout Effector T Cells J. Immunol., February 15, 2003; 170(4): 2004 - 2013. [Abstract] [Full Text] [PDF]

				H. Winter, H.-M. Hu, W. J. Urba, and B. A. Fox Tumor Regression After Adoptive Transfer of Effector T Cells Is Independent of Perforin or Fas Ligand (APO-1L/CD95L) J. Immunol., October 15, 1999; 163(8): 4462 - 4472. [Abstract] [Full Text] [PDF]